Drugs / ARQ761
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03575078 | Jun 2018 → May 2019 | lymphoma | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT02514031 | Mar 2016 → May 2018 | malignant pancreatic neoplasm | University of Texas Southwestern Medical Center | Terminated | No outcome recorded |
| Phase 1 | NCT01502800 | Dec 2011 → Feb 2017 | cancer | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARQ761 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03575078 ↗ |
| Known as | β-LAPACHONE | “PHASE 1 DOSE ESCALATION TRIAL OF β-LAPACHONE (ARQ761) IN COMBINATION WITH PARP INHIBITOR, OLAPARIB, FOR REFRACTORY, ADVANCED SOLID TUMORS” NCT03575078 ↗ |
| Modality | Small molecule | “ARQ 761 is a β-lapachone (β-lap) analogue that exploits the unique elevation of NQO1 found in solid tumours to cause tumour-specific cell death.” PMID 30318513 ↗ Oct 2018 |
| Route | Intravenous | “ARQ 761 will be administered intravenously” NCT01502800 ↗ |